Analysts expect that Bausch Health Companies Inc (NYSE:BHC) will post earnings per share (EPS) of $0.90 for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Bausch Health Companies’ earnings. The lowest EPS estimate is $0.75 and the highest is $1.00. Bausch Health Companies posted earnings per share of $1.03 during the same quarter last year, which would indicate a negative year-over-year growth rate of 12.6%. The company is expected to announce its next earnings report on Tuesday, August 4th.

On average, analysts expect that Bausch Health Companies will report full-year earnings of $3.74 per share for the current year, with EPS estimates ranging from $3.56 to $4.26. For the next financial year, analysts expect that the business will post earnings of $4.40 per share, with EPS estimates ranging from $3.94 to $4.94. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Bausch Health Companies.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.88 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.88. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $2.03 billion. Bausch Health Companies had a negative net margin of 21.96% and a positive return on equity of 84.58%. The business’s revenue was down .2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.03 EPS.

Several research analysts have weighed in on the stock. Royal Bank of Canada lowered their price target on shares of Bausch Health Companies from $25.00 to $24.00 and set a “sector perform” rating on the stock in a report on Friday, May 8th. Wells Fargo & Co increased their target price on shares of Bausch Health Companies from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 30th. Morgan Stanley lowered shares of Bausch Health Companies from an “overweight” rating to an “equal weight” rating in a research report on Thursday, April 2nd. SunTrust Banks decreased their target price on shares of Bausch Health Companies from $25.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Finally, Jefferies Financial Group decreased their target price on shares of Bausch Health Companies from $35.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, April 23rd. One research analyst has rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the stock. Bausch Health Companies has an average rating of “Buy” and an average price target of $32.06.

In other news, Director Holdings L.P. Valueact bought 948,353 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was acquired at an average price of $19.24 per share, with a total value of $18,246,311.72. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John Paulson bought 1,628,920 shares of the stock in a transaction that occurred on Thursday, May 14th. The shares were purchased at an average cost of $15.87 per share, with a total value of $25,850,960.40. The disclosure for this purchase can be found here. Insiders have purchased 4,618,309 shares of company stock valued at $79,509,247 in the last three months. 12.14% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Morgan Stanley increased its stake in Bausch Health Companies by 206.2% in the first quarter. Morgan Stanley now owns 13,614,293 shares of the company’s stock valued at $211,021,000 after purchasing an additional 9,167,662 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Bausch Health Companies by 55.1% in the first quarter. The Manufacturers Life Insurance Company now owns 1,808,047 shares of the company’s stock valued at $27,704,000 after purchasing an additional 642,647 shares in the last quarter. Maverick Capital Ltd. increased its stake in Bausch Health Companies by 5.7% in the first quarter. Maverick Capital Ltd. now owns 153,038 shares of the company’s stock valued at $2,372,000 after purchasing an additional 8,240 shares in the last quarter. X Square Capital LLC bought a new stake in Bausch Health Companies in the first quarter valued at $2,081,000. Finally, Twinbeech Capital LP bought a new stake in Bausch Health Companies in the first quarter valued at $414,000. 68.94% of the stock is owned by institutional investors and hedge funds.

Bausch Health Companies stock traded up $0.10 during trading hours on Thursday, hitting $18.29. The company had a trading volume of 178,238 shares, compared to its average volume of 4,942,722. The firm has a market cap of $6.45 billion, a PE ratio of -3.39, a PEG ratio of 0.45 and a beta of 1.26. Bausch Health Companies has a one year low of $11.15 and a one year high of $31.97. The firm has a 50-day moving average of $18.28 and a 200 day moving average of $22.02.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Recommended Story: What is the Nikkei 225 index?    

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.